Temporal Concept
Minerva’s Roluperidone for Schizophrenia Symptoms Denied Approval by FDA
United States Food and Drug Administration, MFSD1 gene, Symptoms aspect, Schizophrenia, New Drug Application
Janux Shares Surge Over 200% on Promising Early Signs of PSA Response in Prostate Cancer Treatment
Prostate-Specific Antigen, Janux, JANX007, Malignant neoplasm of prostate
ViiV’s Long-Acting Cabenuva Outperforms Daily Oral Therapy in Phase III Study
cabenuva, Daily, Standard of Care, Adherence (attribute), HIV, Participant, daily
FDA Approves Amtagvi as the First One-time Cell Therapy for Solid Tumors: A Groundbreaking TIL Immunotherapy for Advanced Melanoma
Amtagvi, Solid Neoplasm, United States Food and Drug Administration, Lymphocytes, Tumor-Infiltrating
Neurona Raises $120M Bolstered by Promising Early-Stage Data for Epilepsy Cell Therapy NRTX-1001
Epilepsy, NRTX-1001, Seizures, Neurona, Cell Therapy
FDA Awaits Final Decision on Madrigal’s Resmetirom for NASH Treatment with Priority Review and NDA Acceptance Set for March 14, 2024
Nonalcoholic Steatohepatitis, resmetirom, United States Food and Drug Administration, New Drug Application, Priority Review, Fibrosis, Liver, Liver, Madrigal’s, March 14, 2024
Scion Life Sciences Emerges with $310M Fund to Nurture Innovative Biotechnology Startups
Scion, Scion Life Sciences, Investments, Mature